Doern G V, Vautour R, Parker D, Tubert T, Torres B
Department of Clinical Microbiology, University of Massachusetts Medical Center, Worcester 01655.
Antimicrob Agents Chemother. 1991 Jul;35(7):1504-7. doi: 10.1128/AAC.35.7.1504.
The in vitro activity of a new orally administered carbacephem analog of cefaclor, loracarbef (LY163892), was compared with those of cefaclor and several other oral antimicrobial agents against recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis. Loracarbef was found to be slightly more active than cefaclor against H. influenzae and had activity essentially equivalent to that of cefaclor for M. catarrhalis. Resistance to loracarbef was uncommon and was noted only with rare beta-lactamase-producing strains of H. influenzae. On the basis of these observations, loracarbef may be of utility in the management of localized, non-life-threatening infections caused by H. influenzae and M. catarrhalis.
将一种新的口服头孢克洛碳头孢烯类似物氯碳头孢(LY163892)的体外活性与头孢克洛及其他几种口服抗菌药物针对流感嗜血杆菌和卡他莫拉菌近期临床分离株的活性进行了比较。结果发现,氯碳头孢对流感嗜血杆菌的活性略高于头孢克洛,对卡他莫拉菌的活性与头孢克洛基本相当。对氯碳头孢耐药的情况并不常见,仅在罕见的产β-内酰胺酶流感嗜血杆菌菌株中出现。基于这些观察结果,氯碳头孢可能对治疗由流感嗜血杆菌和卡他莫拉菌引起的局部、非危及生命的感染有用。